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             Resting CD4 Tcell                                                          
  ---------- ------------------- ------ ----- ------ ------ ----- ----- ------- ------- ------
  27 (R5)    7.6                 10.4   226   164    21.4   5     221   103.8   41      195
  28 (R5)    4.6                 5.3    \<2   \<2    \<2    \<2   \<2   \<2     \<2     \<2
  35 (RS)    4.6                 \<2    \<2   2      \<2    4.2   \<2   3.1     \<2     \<2
  29 (R5)    17.6                10.1   NA    NA     NA     NA    NA    NA      NA      NA
  50 (D/W)   9.1                 10.5   \<2   11.2   4.1    4.1   \<2   \<2     25.3    \<2
  57 (D/M)   2.6                 10.8   MA    MA     \<2    \<2   NA    MA      446.7   38.8

NFkB activity.

                                                  HIV Copies/10\^6 Naïve CD4+T-Cells   HIV Copies/10\^6 Memory CD4+T-cells   Ratio of infection prevalence   HIV+Naive CD4+T-cells/Total HIV+CD4+T-cells
  ----------------------------------------------- ------------------------------------ ------------------------------------- ------------------------------- ---------------------------------------------
  R5                                              2,962 (129--10,668)                  9,931 (1037--11,808)                  0.7 (0.2--4.3)                  53% (25%--80%)
  DM                                              14,733 (1,344--135,120)              930 (151--29,702)                     8.9 (6.6--13.0)                 92% (88%--95%)
  P-value[§](#TF36_TF0001){ref-type="table-fn"}   0.31                                 0.61                                  0.04                            0.07

Comparing R5 to DM with Kruskal-Wallis Test.

HIV-Reservoir by CCR5/DM Tropism.

  Patient   Sample Collection Time (months from allogeneic SCT)   Total HIV-1 DNA (copies/million PBMCs)   2-LTR HIV-1 DNA (copies/million PBMCs)   Plasma HIV-1 RNA (copies/ml)
  --------- ----------------------------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------
  **A**     −0.5 (pre-SCT)                                        **144**                                  ND                                       \<3
  **A**     2                                                     **87**                                   ND                                       \<3
  **A**     8                                                     ND                                       ND                                       \<3
  **A**     14                                                    ND                                       ND                                       \<3
  **B**     −0.2 (pre-SCT)                                        **96**                                   ND                                       \<3
  **B**     3                                                     **281**                                  ND                                       \<3
  **B**     9                                                     ND                                       ND                                       \<3
  **B**     17                                                    ND                                       ND                                       \<3

ND=Target Not Detected

Quantification of Peripheral Blood HIV Reservoirs.

![Comparison of anti-APOBEC3G activity of Vif From AI, CP and EC patients.\
Each dot represents mean RLU of each patient.](JIAS-15-18438-42-g001){#F42_F0005}
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![**Picture of prototype TFV and TFV/LNG IVRs**.](JIAS-15-18438-62-g001){#F62_F0007}
